Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy
✍ Scribed by Aristotle Bamias; Theodora Psaltopoulou; Maria Sotiropoulou; Dimitrios Haidopoulos; Evangelos Lianos; Evangelos Bournakis; Christos Papadimitriou; Alexandros Rodolakis; George Vlahos; Meletius A. Dimopoulos
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 148 KB
- Volume
- 116
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND:
Mucinous and clear cell histology have been associated with adverse prognosis in ovarian carcinomas. The authors compared the outcome of these subtypes with that of serous tumors in patients who were treated with combination paclitaxel/platinum at their center.
METHODS:
Four hundred twenty patients with histologically confirmed, serous (n = 367), mucinous (n = 24), or clear cell (n = 29) ovarian carcinomas, International Federation of Gynecology and Obstetrics stage III or IV disease, and who were treated with paclitaxel/platinum after cytoreductive surgery were included in this analysis.
RESULTS:
The median overall survival for each histological subtype was 47.7 months (95% confidence interval [CI], 37.7‐57.7 months) for serous, 15.4 months (95% CI, 4.2‐26.6 months) for mucinous, and 36.6 months (95% CI, 22.7‐50.5 months) for clear cell carcinomas. Cox regression analysis showed that mucinous histology was an independent predictor of poor prognosis compared with serous tumors (hazard ratio, 0.360; 95% CI, 0.215‐0.603; P = .001). In contrast, such a difference between clear cell and serous carcinomas was not found (P = .337). Median survival of patients with mucinous tumors and residual disease >2 cm was poor, averaging 7.1 months (95% CI, 4.6‐9.6 months).
CONCLUSIONS:
Mucinous but not clear cell histology is associated with significantly worse prognosis in advanced ovarian cancer treated with combination platinum/paclitaxel. Different therapeutic strategies should be studied in this entity. Cancer 2010. © 2010 American Cancer Society.